Cambio Healthcare Systems Investcorp Private Equity in Healthcare

Cambio Healthcare Systems Investcorp is a significant player in the private equity space, particularly in the healthcare sector.

Investcorp's investment in Cambio Healthcare Systems is a notable example of its focus on healthcare.

Cambio Healthcare Systems is a leading provider of healthcare software and services, with a strong presence in Europe.

Investcorp's investment in Cambio was a strategic move to support the company's growth and expansion plans.

The investment enabled Cambio to strengthen its market position and increase its offerings to healthcare providers.

Cambio's software solutions and services aim to improve patient care and outcomes, as well as enhance operational efficiency for healthcare organizations.

Take a look at this: Quanta Services Inc Investor Relations

Investcorp has acquired Cambio Healthcare Systems AB from Valedo Partners Fund II AB and a group of minority investors.

Valedo invested in Cambio in 2012, marking the beginning of a transformation period for the company.

If this caught your attention, see: Cuanto Es 100 Dólares En Lempiras

Investcorp has made a significant acquisition in the healthcare sector by acquiring Cambio Healthcare Systems AB from Valedo Partners Fund II AB and a group of minority investors.

Investcorp has partnered with Valedo to acquire Cambio, which was initially invested in by Valedo in 2012.

The acquisition marks a major milestone in Cambio's transformation, which was driven by Valedo, the management team, and employees.

The two founders of Cambio, Tomas Mora-Morrison and Håkan Mattsson, are among the minority investors involved in the sale.

Regulators are increasingly looking beyond issues of price and competition and have a keen focus on protecting or encouraging innovation.

Any investment in a company with an R&D division is likely to attract scrutiny.

Cambio Healthcare Systems has a strong track record of growth, with an average annual growth rate of 17% during Valedo's ownership period.

This impressive growth can be attributed to the company's focus on increasing new customer sales and strengthening its collaboration with existing customers.

Cambio's business model has been structured to achieve increased customer value, which has enabled the company to offer e-health solutions with world-leading functionality.

The company has also made two strategically important acquisitions, establishing Cambio on the Swedish market for social care information systems and strengthening its presence in the United Kingdom.

Under the leadership of CEO Peter Gille, Cambio has transformed into a leading regional European supplier of e-health solutions since Valedo invested in the company in 2012.

Cambio's commitment to software development and innovation capabilities has enabled the company to offer e-health solutions that improve the quality of care and increase healthcare provider productivity.

Expand your knowledge: Prior Authorization Solutions

Private Equity in Healthcare is a rapidly growing field, with investments reaching new records in 2019.

The US market has historically been a focus for global sponsors, but investments like Nestlé Skin Health have highlighted the scale and quality of businesses in Europe.

European healthcare companies can have global footprints and be exposed to positive secular trends in both developed and emerging markets.

The COVID-19 pandemic is putting healthcare provision and security in the spotlight, creating compelling opportunities for private equity to invest in companies that generate attractive returns while reducing costs and increasing efficiency.

Expand your knowledge: Global X Etf Price

Private equity investment in healthcare has been on an upward trajectory over the last decade, achieving new records in 2019.

The US market has historically been the focus of many global sponsors, but investments like Nestlé Skin Health have highlighted the scale and quality of businesses in Europe.

European healthcare companies can have global footprints and be exposed to positive secular trends in both developed and emerging markets.

Europe, with strong links to emerging markets particularly in Africa and South Asia, as well as international capital markets expertise, often serves as a launch pad for private equity investment into many parts of the developing world.

The COVID-19 pandemic is putting healthcare provision and security in the spotlight, creating compelling opportunities for private equity to invest in companies that generate attractive returns while reducing costs, increasing efficiency, and delivering better outcomes.

Deals will be subject to greater regulatory scrutiny and will require more careful due diligence to navigate existing and emerging requirements.

Private equity firms need to understand the regional landscape in European healthcare to identify and manage key due diligence risks and have clear answers for regulators' searching questions.

Check this out: Global Investment Returns Yearbook

Vertical integration is a key strategy for private equity firms in healthcare. This involves acquiring a company and then expanding its operations to include multiple stages of production or delivery of a product or service.

Kohlberg Kravis Roberts (KKR) is a prime example of this, as they acquired a controlling stake in Fresenius Medical Care in 2002 and then expanded its operations to include dialysis clinics, equipment manufacturing, and other services.

By doing so, KKR was able to increase Fresenius Medical Care's revenue and profitability, making it a highly successful investment.

In healthcare, vertical integration can also involve acquiring a company that provides a complementary service, such as a pharmacy or laboratory.

This can help private equity firms to increase their market share and improve their competitive position in the industry.

If this caught your attention, see: Alternative Asset Management Firms

During Valedo's ownership, the company's business model was structured to generate increased customer value. This led to strengthened market positions in Sweden and the United Kingdom.

The owners took a long-term approach, not taking any dividends and instead investing substantial amounts in the business. This allowed Cambio to focus on growth and development.

Key personnel were offered the opportunity to invest in Cambio, creating a common agenda with the owners. This alignment of interests helped drive the company's success.

Here are some key initiatives implemented during Valedo's ownership:

Biopharma is becoming a more attractive investment opportunity for private equity firms, despite the higher risk of failure and cash demands of research and development.

Historically, private equity has been less focused on biopharma, but that's changing as sponsors explore opportunities in newer ventures and more mature companies requiring investment and expertise.

The COVID-19 pandemic has forced many biopharma companies to put clinical trials on hold, rendering existing trial samples useless and forcing new priorities.

In the first half of 2020, at least 43% of clinical trials identified by the US National Library of Medicine as stopped or postponed since January 2020 cited COVID-19 as the reason.

Private equity firms may adopt alternative investment structures, such as preferred equity or contingent value rights, to protect against downside risks while capturing upside potential.

These structures can include earn-outs, milestone payments, and agreements for access to royalty streams.

Worth a look: List of Impact Investing Firms